Heart attack risk halved in adults with heart disease taking tailored vitamin D doses

A preliminary study presented at the American Heart Association’s Scientific Sessions 2025 indicates that adults with heart disease and a prior heart attack who received personalized vitamin D supplementation, tailored to achieve optimal blood levels (40-80 ng/mL), experienced a 52% reduction in the risk of subsequent heart attacks. The TARGET-D trial revealed that 85% of participants initially had insufficient vitamin D, with nearly half requiring doses exceeding 5,000 IU daily to reach target levels, significantly higher than the FDA's recommended 800 IU. While not significantly impacting broader outcomes like death or stroke, these findings suggest that individualized vitamin D management, based on blood testing, could be a crucial intervention for preventing recurrent heart attacks in this patient population, pending further peer-reviewed research.

Analysis

The TARGET-D randomized clinical trial, presented at AHA Scientific Sessions 2025, indicates that adults with heart disease and a prior heart attack who received personalized vitamin D supplementation achieved a significant 52% reduction in the risk of a subsequent heart attack. This specific outcome highlights a potential targeted intervention for secondary prevention in a high-risk cardiac population.

The study's methodology emphasized tailored dosing, with nearly 52% of participants requiring over 5,000 IU of vitamin D daily to reach optimal blood levels (40-80 ng/mL), significantly exceeding the FDA's 800 IU daily value. This underscores the prevalence of vitamin D insufficiency, with 85% of participants starting below 40 ng/mL, and the need for individualized management.

While beneficial for heart attack prevention, the trial did not demonstrate a significant reduction in the broader primary outcome encompassing death, heart failure hospitalization, or stroke. Investors should note the preliminary nature of these findings, as they are from an abstract and not yet peer-reviewed, alongside limitations regarding participant demographics and study size.

Key Decisions for Investors

• Monitor the publication of the full, peer-reviewed TARGET-D manuscript and subsequent larger-scale trials for validation of these preliminary findings.
• Evaluate potential long-term implications for companies involved in vitamin D diagnostic testing and high-dose vitamin D supplement manufacturing, given the personalized dosing approach.
• Assess any potential shifts in clinical guidelines or healthcare policy regarding vitamin D screening and supplementation for cardiovascular patients, which could create new market opportunities or challenges.